This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Blumenthal, R. D. Articles by Goldenberg, D. M. Search for Related Content PubMed PubMed Citation Articles by Blumenthal, R. D. Articles by Goldenberg, D. M.

Reduction of Radioantibody-induced Myelotoxicity in Hamsters by Recombinant Interleukin-1

Center for Molecular Medicine and Immunology [R. D. B., R. M. S., D. J. S., D. M. G.], University of Medicine and Dentistry of New Jersey, and Immunomedics, Inc. [H. J. H.], Newark, New Jersey 07103

Recombinant human interleukin 1 (IL-1) administered i.p. to tumor-bearing hamsters results in a dose-dependent 2- to 5-fold increase in total peripheral white blood cells. These levels remain elevated for 2 to 3 wk and then decline to base-line levels. Pretreatment of animals with similar doses of IL-1 prevents radioimmunotherapy-induced destruction of the radiosensitive hematopoietic system. Furthermore, recovery from radioimmunotherapy-induced myelosuppression is possible if animals are given IL-1 1 wk after radioimmunotherapy treatment. Thus, both protection and rescue from the hematopoietic damage associated with radioantibody treatment are feasible by pre- or posttreatment with IL-1.

¹ To whom requests for reprints should be addressed, at Center for Molecular Medicine and Immunology, 1 Bruce Street, Newark, NJ 07103.

Received 3/22/88. Revised 6/ 9/88. Accepted 6/24/88.